Versartis, Inc. (VSAR)

[loup]

cfo leaving may be a two-fold - they obviously have to reduce expenses which they have according to the financial information announced after the market close last night- they have the right personnel in place to cover their needs. when a strategic transaction takes place those coming in will want to put their own personal financial cfo in charge. they have a large number of options available to them that they discuss in last night's financial release and they have over 100 million dollars in cash. they can let progress happen - other entities who have a need for their technology acquire rights or they can make something happen continue to pursue the outcome of the concluded test trials by year end. the fact that patients can dose less is huge and the fact that their product may require no refrigeration is even a bigger plus
they also talk about a pipeline of four products - so there are other opportunities out there
there is always some risk with this type of investment but the assets they have should be worth billions to competitors ( if my assumptions are correct ) of course there will be dilution - but currently there are under 40 million shares outstanding and cash is over 100 million - do the math - the stock is currently highly undervalued